STOCK TITAN
  1. Home
  2. Sec-filings
  3. MREO
  4. [Form 4] Mereo BioPharma Group plc Insider Trading Activity

Mereo BioPharma (MREO) grants CEO Denise Scots-Knight new option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mereo BioPharma Group plc reported that Chief Executive Officer and director Denise Scots-Knight received new stock option awards on February 1, 2026. She was granted options to buy 1,035,000 American Depositary Shares at $0.44, 345,000 at $1.00, and 480,000 at $0.44, all held directly.

For the 1,035,000-share grant, 25% will vest and become exercisable on February 1, 2027, with the balance vesting in equal monthly installments over the following three years. The 480,000-share grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.

Positive

  • None.

Negative

  • None.
Insider Scots-Knight Denise
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Share Options (Right to buy) 1,035,000 $0.00 --
Grant/Award Share Options (Right to buy) 345,000 $0.00 --
Grant/Award Share Options (Right to buy) 480,000 $0.00 --
Holdings After Transaction: Share Options (Right to buy) — 1,035,000 shares (Direct)
Footnotes (1)
  1. 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scots-Knight Denise
(Last) (First) (Middle)
C/O MEREO BIOPHARMA GROUP PLC
4TH FLOOR, ONE CAVENDISH PLACE
(Street)
LONDON X0 W1G 0QF
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mereo BioPharma Group plc [ MREO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Options (Right to buy) $0.44 02/01/2026 A 1,035,000 (1) 02/01/2036 American Depositary Shares(2) 1,035,000 $0.00 1,035,000 D
Share Options (Right to buy) $1 02/01/2026 A 345,000 (1) 02/01/2036 American Depository Shares(2) 345,000 $0.00 345,000 D
Share Options (Right to buy) $0.44 02/01/2026 A 480,000 (3) 02/01/2036 American Depository Shares(2) 480,000 $0.00 480,000 D
Explanation of Responses:
1. 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.
2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
3. Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.
/s/ Christine Fox, by power of attorney 02/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mereo BioPharma (MREO) report for Denise Scots-Knight?

Mereo BioPharma reported that CEO and director Denise Scots-Knight received several stock option grants on February 1, 2026. These derivative awards give her rights to acquire American Depositary Shares under specific exercise prices and vesting schedules described in the filing’s footnotes.

How many stock options were granted to the Mereo BioPharma CEO on February 1, 2026?

On February 1, 2026, Denise Scots-Knight was granted three stock option awards: 1,035,000 options at $0.44, 345,000 options at $1.00, and 480,000 options at $0.44. All are reported as directly owned derivative securities following the transactions.

What are the vesting terms for Denise Scots-Knight’s 1,035,000 Mereo BioPharma options?

For the 1,035,000-share option grant, 25% of the underlying shares will vest and become exercisable on February 1, 2027. The remaining 75% will then vest in equal monthly installments over the subsequent three years, according to the filing’s explanation of responses.

How do Mereo BioPharma’s American Depositary Shares relate to ordinary shares?

Each Mereo BioPharma American Depositary Share, or ADS, represents five ordinary shares of the issuer. The filing states that each ADS corresponds to five ordinary shares with a nominal value of GBP 0.003 per ordinary share, linking the derivative grants to underlying equity.

What is the vesting schedule for the 480,000-share option grant at Mereo BioPharma?

The 480,000-share stock option grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. This schedule means portions of the award become exercisable each month during that year, subject to the terms of the option agreement.

Are the reported Mereo BioPharma options held directly or indirectly by Denise Scots-Knight?

All three reported stock option grants are listed as directly owned by Denise Scots-Knight. The Form 4 data show the ownership form as “D” for direct, and there are no footnotes indicating that the options are held through another entity or on an indirect basis.